TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05696704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral: Mindfulness Based Cognitive Therapy
Description: Individual tele-therapy 12 to 16 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral: Behavior Activation
Description: Individual therapy 12 to 16 weeks
Study: NCT04845698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-Dashboard
Description: i-Dashboard is a team-designed, patient-centered electronic medical record viewer, which retrieves data from multiple databases and provides a quick representation of essential metrics for each patient.
Study: NCT05715307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive training for endocrinologists in T2DM management
Description: One-week intensive experiential training for endocrinologists includes a 1-week hospitalization experience at Ruijin Hospital, involving health examinations, results interpretation, and integrated training courses for T2DM management.~During the patient intervention period, endocrinologists will each manage approximately 10 T2DM patients, conduct regular follow-ups, and participate in regular training sessions, including experience-sharing meetings.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular training for endocrinologists in T2DM management
Description: Regular training and communication are implemented by Ruijin Hospital under the guidance of T2DM management.~During the patient intervention period, endocrinologists will each manage approximately 10 T2DM patients, conduct regular follow-ups, and receive regular routine training.
Study: NCT04724460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long DOAC
Description: Administration of Rivaroxaban for 18 months
Study: NCT05794971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib and DIBIRI
Description: Drug: Regorafenib Regorafenib will be given 3 weeks on/1 week off (initial dose: 80 mg od po.)~Drug: Irinotecan it will be mixed in eluting-beads and injected in the tumor.~Procedure: TACE Transcatheter arterial chemoembolization（TACE）is a minimally invasive procedure performed to decrease the tumor's blood supply.~Device: drug eluting-bead The eluting-bead,loaded with irinotecan (DEBIRI) to treat patients with hepatic metastases from colorectal cancer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Drug: Regorafenib Regorafenib will be given 3 weeks on/1 week off (initial dose: 80 mg od po.)
Study: NCT06501352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Additive to Local anesthetic mixture
Study: NCT05148208

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Creatine supplementation to dialysate
Description: Creatine supplementation to dialysate
Study: NCT04724460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short DOAC
Description: Administration of Rivaroxaban for 6 months
Study: NCT05148208

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Creatine supplementation to dialysate
Description: Creatine supplementation to dialysate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Creatine supplementation to dialysate
Description: Creatine supplementation to dialysate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Creatine supplementation to dialysate
Description: Creatine supplementation to dialysate

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Creatine supplementation to dialysate
Description: Creatine supplementation to dialysate
Study: NCT05397873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback training
Description: The training of oculomotor functions is done on the biofeedback module of a microperimeter MAIA.
Study: NCT06182280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP4T
Description: PrEP4T is an individualized TMSM-specific intervention adapted from The Fenway Model. PrEP4T consists of online one-on-one sessions between a peer and a participant using a strengths-based case management manualized curriculum. Peer navigators (PNs) share transmasculine community membership with participants and are trained to provide linkages. They use an individualized approach to navigate barriers, apply an assets-based frame to promote resiliencies, and pragmatically leverage these to improve biomedical HIV prevention outcomes. PNs utilize techniques from established behavior change models (e.g., Motivational Interviewing; Transtheoretical Model) in PrEP decision-making.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP4T
Description: PrEP4T is an individualized TMSM-specific intervention adapted from The Fenway Model. PrEP4T consists of online one-on-one sessions between a peer and a participant using a strengths-based case management manualized curriculum. Peer navigators (PNs) share transmasculine community membership with participants and are trained to provide linkages. They use an individualized approach to navigate barriers, apply an assets-based frame to promote resiliencies, and pragmatically leverage these to improve biomedical HIV prevention outcomes. PNs utilize techniques from established behavior change models (e.g., Motivational Interviewing; Transtheoretical Model) in PrEP decision-making.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LS4TM
Description: LS4TM is a theory-based peer-delivered small group-based behavioral intervention to reduce HIV risk and address mental health-related effects of stigma for TMSM. Groups will be led by trained peer navigator staff and comprise no more than 10 participants per cohort.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LS4TM
Description: LS4TM is a theory-based peer-delivered small group-based behavioral intervention to reduce HIV risk and address mental health-related effects of stigma for TMSM. Groups will be led by trained peer navigator staff and comprise no more than 10 participants per cohort.
Study: NCT06501352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Additive to Local anesthetic mixture
Study: NCT04842422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 3.75% Cream
Description: Imiquimod 3.75% Cream
Study: NCT06501352

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Control
Study: NCT06173141

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low- to moderate-continuous intensity cycling exercises:
Description: aerobic exercise during dialysis using Pedal machine at low- to moderate continuous intensity rating from 11 to 13 on the Borg scale for 15-30 minutes.~warming up and cool down (approximately 10 minutes) in form of free active exercise of the lower extremities

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: moderate- to high-interval intensity cycling exercises
Description: aerobic exercise during dialysis using Pedal machine at moderate-to-high interval intensity rating from 12 to 15 on the Borg scale for 15-30 minutes.~warming up and cool down (approximately 10 minutes) in form of free active exercise of the lower extremities

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: hemodialysis sessions only
Description: hemodialysis sessions only
Study: NCT05812300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Freshly manufactured 35 kDa hyaluronan fragment
Description: The study was an open-label clinical trial. A pre- and posttreatment controlled study approach was used, whereby the investigator injected 35 kDa hyaluronan fragment HA35 into the periodontal pocket in a single dose of 100 mg. The distribution of the injection amount was determined by the location of gingival inflammation.
Study: NCT04215458

Intervention type: OTHER
Group type: OTHER
Intervention: sample collection (swap or tape strip)
Description: collection of swap or tape strip to determine yeast colonization in skin
Study: NCT05527405

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The MapHabit System
Description: The MapHabit System (MHS) is a commercially available visual mapping software application that utilizes visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application will be made available to families through compatible smartphones and tablets. Depending on the condition, participants will receive a specific version of the application. The experimental condition will receive the version that incorporates gamified content and structure.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The MapHabit System
Description: The MapHabit System (MHS) is a commercially available visual mapping software application that utilizes visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application will be made available to families through compatible smartphones and tablets. Depending on the condition, participants will receive a specific version of the application. The experimental condition will receive the version that incorporates gamified content and structure.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device.
Study: NCT06005623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENS Motion + Motivational Feedback
Description: To weeks prior to surgery and in a 12-week period following discharge after TKA/UKA patients will be equipped with a discrete patch and built-in accelerometer (SENS Motion, Denmark, Copenhagen) attached on the thigh of the leg not undergoing surgery.~Following discharge after TKA/UKA patients randomized to the intervention-group will receive the app (SENS motion). On their provided app, patients will be able to choose between two tabs. Tab 1 will allow patients to view predefined goals, all of which are locations in a self-selected city. The sensor will measure the physical activity and daily rhythm of the patient, and accelerometer counts will be converted into daily steps, which will be visible to the patients. In Tab 2, patients will be able to see graphical representations of their daily activity as well as their history during the period in which they have worn the accelerometer. The graphical representations include: Daily steps, physical active minutes, and type of activity.
Study: NCT05834413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy plus TCM 1&ICIs plusTCM2 placebo
Description: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang and Xu Ling. Package of granules is made into two types with functions such as tonifying the stomach and nourishing the blood recipe, benefiting Qi Yin and detoxification and resolving masses recipe. The herbal treatment is adapted to the syndromes.~Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy.~ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: chemotherapy plus TCM 1placebo &ICIs plus TCM2 placebo
Description: Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy.~ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy.
Study: NCT05864170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: β-globin restored autologous hematopoietic stem cells
Description: β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q
Study: NCT06281288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: Cognitive behavioral therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: Cognitive behavioral therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: Cognitive behavioral therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Moderate intensity (\~63% maximum heart rate; HRmax) aerobic (\~25 min) and resistance (\~25 min) activities
Study: NCT04402073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonidegib
Description: Sonidegib is a selective smoothened inhibitor that inhibits the sonic hedgehog-signaling pathway. It is used in patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (CIS) is a platinum derivate used in the treatment in several epithelial tumours. The application route is through the veins.

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Cisplatin (CIS) is a platinum derivate used in the treatment in several epithelial tumours. The application route is through the veins.
Study: NCT06281288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Moderate intensity (\~63% maximum heart rate; HRmax) aerobic (\~25 min) and resistance (\~25 min) activities
Study: NCT05345054

Intervention type: OTHER
Intervention: no intervention
Description: This study will not involve an intervention of any sort. Participants will either take a survey or undergo an interview, and those taking the survey will have clinical data captured.

Intervention type: OTHER
Intervention: no intervention
Description: This study will not involve an intervention of any sort. Participants will either take a survey or undergo an interview, and those taking the survey will have clinical data captured.

Intervention type: OTHER
Intervention: no intervention
Description: This study will not involve an intervention of any sort. Participants will either take a survey or undergo an interview, and those taking the survey will have clinical data captured.
Study: NCT04903197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAY736
Description: VAY736 is a fully human IgG1 monoclonal antibody (mAb) which targets the B cell activating factor receptor (BAFF-R) expressed on the surface of differentiated B cells and modulates their function.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAY736
Description: VAY736 is a fully human IgG1 monoclonal antibody (mAb) which targets the B cell activating factor receptor (BAFF-R) expressed on the surface of differentiated B cells and modulates their function.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAY736
Description: VAY736 is a fully human IgG1 monoclonal antibody (mAb) which targets the B cell activating factor receptor (BAFF-R) expressed on the surface of differentiated B cells and modulates their function.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAY736
Description: VAY736 is a fully human IgG1 monoclonal antibody (mAb) which targets the B cell activating factor receptor (BAFF-R) expressed on the surface of differentiated B cells and modulates their function.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Immune-modulatory agent that enhances activation of NK cells.
Study: NCT04402073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Lomustine is a nitrosourea used in the treatment of brain tumours and Hodgkin's disease. The application route is oral.

Intervention type: DRUG
Group type: OTHER
Intervention: Lomustine
Description: Lomustine is a nitrosourea used in the treatment of brain tumours and Hodgkin's disease. The application route is oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine sulfate (VCR) is an inhibitor of microtubule formation in the mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. Vincristine sulfate is indicated in acute leukemia, Hodgkin's disease, non-Hodgkin's lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor. The application route is through the vein.

Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: Vincristine sulfate (VCR) is an inhibitor of microtubule formation in the mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. Vincristine sulfate is indicated in acute leukemia, Hodgkin's disease, non-Hodgkin's lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor. The application route is through the vein.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiotherapy to the cranio-spinal axis of 35.2 Gy in 22 daily fractions of 1.6 Gy, followed by an additional boost to the tumour site of 19.8 Gy in 11 daily fractions of 1.8 Gy, summing up to a total dose of 55.0 Gy in 33 daily fractions of 1.6/1.8 Gy.
Study: NCT04903197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Immune-modulatory agent that enhances activation of NK cells.
Study: NCT06369623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monetary Incentive Delay Task
Description: The Monetary Incentive Delay functional Magnetic Resonance Imaging task is well-characterized and commonly utilized in research settings to measure neural activation between win and loss conditions, as well as between phases of anticipation and consummation/outcome. A recent meta-analysis indicates that the task has been used in over 80 studies and 5,000 subjects as of Year 2022. The task is also valid and appropriate for use in children and adolescents, as demonstrated by its inclusion in National Institute on Drug Abuse ABCD study. The task is utilized for its short-lived, reversible, and/or benign effects on brain activation (e.g., brief processing of a reward cue).
Study: NCT04402073

Intervention type: RADIATION
Group type: OTHER
Intervention: radiotherapy
Description: Radiotherapy to the cranio-spinal axis of 35.2 Gy in 22 daily fractions of 1.6 Gy, followed by an additional boost to the tumour site of 19.8 Gy in 11 daily fractions of 1.8 Gy, summing up to a total dose of 55.0 Gy in 33 daily fractions of 1.6/1.8 Gy.
Study: NCT04937166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DSP107
Description: DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine is an analog of the pyrimidine nucleoside cytidine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is a B-cell lymphoma (BCL)-2 inhibitor
Study: NCT06475820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: GVHD prevention using a combination of post-transplantation cyclophosphamide~Prevention of GVHD:~Cyclophosphamide 80 mg/kg/course on the days +3, +4 Abatacept 10 mg/kg/day on the days +5, +14, +28, +60, +90 Vedolizumab 10 mg/kg/day, max. 300 mg on the days 0, +14, +28, +60 Baricitinib 4 mg/day per os (patient age \> 9 years), 2 mg/day (patient age \< 9 years), from day -3 to day +90 (after HSCT), orally, once a day.
Study: NCT04870281

Intervention type: DEVICE
Intervention: CRT-DX
Description: Evaluation of overall health, including heart failure and atrial fibrillation improvement, changes in physical fitness, and general quality of life.
Study: NCT05579925

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: CM310 600 mg + 300 mg, subcutaneous injection
Study: NCT04176575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture involves inserting thin needles into precise points on the body, known as acupuncture points, for therapeutic effect. Acupuncture will be provided by a licensed acupuncturist utilizing Dr. Tan's Balancing Method.
Study: NCT05948098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated Tucking Position
Description: a sub-form of method of nesting the baby and the procedure of bringing the body to middle or even close position by holding the upper and lower extremities of the baby in flexion with hands

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gentle Human Touch
Description: It is a form of healing touch
Study: NCT06085950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Ultrasonic Stimulation prototype
Description: Transcranial Ultrasonic Stimulation prototype delivers personalized low-intensity ultrasound stimulation
Study: NCT05464589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation along with pelvic floor muscle srengthening
Description: Pelvic floor muscles strengthening:~Pelvic floor muscles training involves Kegel's exercises. Kegel exercises improve the function and tone of the pelvic floor. Kegel exercises represent the voluntary contraction and relaxation of the levator ani muscle (principally the pubococcygeus and puborectalis portions), which supports the vagina, bladder, and urethra. The slow contractions help with muscle strengthening.~Transcutaneous electrical stimulation of Tibial Nerve:~Transcutaneous Tibial nerve stimulation is a form of treatment technique that involves the use of electrical impulses to address urinary symptoms and target the lower urinary tract.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscles strengthening
Description: Pelvic floor muscles strengthening:~Pelvic floor muscles training involves Kegel's exercises. Kegel exercises improve the function and tone of the pelvic floor. Kegel exercises represent the voluntary contraction and relaxation of the levator ani muscle (principally the pubococcygeus and puborectalis portions), which supports the vagina, bladder, and urethra. The slow contractions help with muscle strengthening.
Study: NCT05542680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cushion
Description: In the intervention group, the special cushion for semi recumbent position was used
Study: NCT05791799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel
Description: Etongestrel implant will be implanted subcutaneously in the participant's non-dominant arm for one year
Study: NCT05368428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Undergo TENS